Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 23
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Synthesis and Leishmanicidal activity of novel urea, thiourea, and selenourea derivatives of diselenides

  • Díaz, Marta
  • Lucio, Hector de
  • Moreno, Esther
  • Espuelas, Socorro
  • Aydillo, Carlos
  • Jiménez Ruiz, Antonio
  • Toro, Miguel Ángel
  • Gutiérrez, Killian Jesús
  • Martínez Merino, Víctor
  • Cornejo Ibergallartu, Alfonso
A novel series of thirty-one N-substituted urea, thiourea, and selenourea derivatives containing diphenyldiselenide entities were synthesized, fully characterized by spectroscopic and analytical methods, and screened for their in vitro leishmanicidal activities. The cytotoxic activity of these derivatives was tested against Leishmania infantum axenic amastigotes, and selectivity was assessed in human THP-1 cells. Thirteen of the synthesized compounds showed a significant antileishmanial activity, with 50% effective concentration (EC50) values lower than that for the reference drug miltefosine (EC50, 2.84 mu M). In addition, the derivatives 9, 11, 42, and 47, with EC50 between 1.1 and 1.95 mu M, also displayed excellent selectivity (selectivity index ranged from 12.4 to 22.7) and were tested against infected macrophages. Compound 11, a derivative with a cyclohexyl chain, exhibited the highest activity against intracellular amastigotes, with EC50 values similar to those observed for the standard drug edelfosine. Structure-activity relationship analyses revealed that N-aliphatic substitution in urea and selenourea is recommended for the leish-manicidal activity of these analogs. Preliminary studies of the mechanism of action for the hit compounds was carried out by measuring their ability to inhibit trypanothione reductase. Even though the obtained results suggest that this enzyme is not the target for most of these derivatives, their activity comparable to that of the standards and lack of toxicity in THP-1 cells highlight the potential of these compounds to be optimized for leishmaniasis treatment., The authors thank the Foundation for Applied Medical Investigation (FIMA), University of Navarra. They also acknowledge the Ministerio de Educación y Ciencia, Spain (grant SAF2015-64629-C2), and Comunidad de Madrid (BIPEDD-2-CM ref. S-2010/BMD-2457) for financial support. They also thank the Caixa Foundation, Roviralta, and Ubesol for supporting this research. This work, including the efforts of M.D., was funded by Foundation for Applied Medical Investigation (ISTUN-API-2011/02). This work, including the efforts of A.J.-R., was funded by Ministerio de Educacion y Ciencia, Spain (grant SAF2015-64629-C2), and Comunidad de Madrid (BIPEDD-2-CM ref. S-2010/BMD-2457).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antiviral activity of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones against chikungunya virus targeting the viral capping nsP1

  • Gigante, Alba
  • Gómez-SanJuan, Asier
  • Delang, Leen
  • Li, C.
  • Bueno, Oskia
  • Gamo, Ana María
  • Priego, Eva María
  • Camarasa Rius, María José
  • Jochmans, D.
  • Leyssen, Pieter
  • Decroly, E.
  • Coutard, Bruno
  • Querat, Guilles
  • Neyts, Johan
  • Peréz-Pérez, María-Jesús
Chikungunya virus (CHIKV) is a re-emerging alphavirus transmitted to humans by Aedes mosquitoes. Since 2005, CHIKV has been spreading worldwide resulting in epidemics in Africa, the Indian Ocean islands, Asia and more recently in the Americas. CHIKV is thus considered as a global health concern. There is no specific vaccine or drug available for the treatment of this incapacitating viral infection. We previously identified 3-aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones as selective inhibitors of CHIKV replication and proposed the viral capping enzyme nsP1 as a target. This work describes the synthesis of novel series of related compounds carrying at the aryl moiety a methylketone and related oximes combined with an ethyl or an ethyl-mimic at 5-position of the triazolopyrimidinone. These compounds have shown antiviral activity against different CHIKV isolates in the very low μM range based on both virus yield reduction and virus-induced cell-killing inhibition assays. Moreover, these antivirals inhibit the in vitro guanylylation of alphavirus nsP1, as determined by Western blot using an anti-cap antibody. Thus, the data obtained seem to indicate that the anti-CHIKV activity might be related to the inhibition of this crucial step in the viral RNA capping machinery., A. G. has received a JAE-predoctoral fellowship financed by the CSIC and the FSE (Fondo Social Europeo).We thank Caroline Collard and Kim Donckers for their excellent technical assistance in the acquisition of the antiviral data. This work has been supported by grants of the MINECO/FEDER (SAF2015-64629-C2-1-R), BIPEDD-2- CM (S2010/BMD-2457) and by EU F7 projects SILVER and EUVIRNA (grant numbers 260644 and 264286, respectively)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy?

  • Castro, Sonia de
  • Camarasa Rius, María José
HIV infection still has a serious health and socio-economical impact and is one of the primary causes of morbidity and mortality all over the world. HIV infection and the AIDS pandemic are still matters of great concern, especially in less developed countries where the access to highly active antiretroviral therapy (HAART) is limited. Patient compliance is another serious drawback. Nowadays, HAART is the treatment of choice although it is not the panacea. Despite the fact that it suppresses viral replication at undetectable viral loads and prevents progression of HIV infection into AIDS HAART has several pitfalls, namely, long-term side-effects, drug resistance development, emergence of drug-resistant viruses, low compliance and the intolerance of some patients to these drugs. Moreover, another serious health concern is the event of co-infection with more than one pathogen at the same time (e.g. HIV and HCV, HBV, herpes viruses, etc). Currently, the multi-target drug approach has become an exciting strategy to address complex diseases and overcome drug resistance development. Such multifunctional molecules combine in their structure pharmacophores that may simultaneously interfere with multiple targets and their use may eventually be more safe and efficacious than that involving a mixture of separate molecules because of avoidance or delay of drug resistance, lower incidence of unwanted drug-drug interactions and improved compliance. In this review we focus on multifunctional molecules with dual activity against different targets of the HIV life cycle or able to block replication, not only of HIV but also of other viruses that are often co-pathogens of HIV. The different approaches are documented by selected examples., The authors thank Prof. Jan Balzarini and Prof. Federico Gago for careful reading and constructive comments on this manuscript. The research work of the authors, was generously supported by the Spanish MINECO/FEDER (Grant SAF2015-64629-C2-1-R)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of the Replication of Different Strains of Chikungunya Virus by 3-Aryl-[1,2,3]triazolo[4,5- d] pyrimidin-7(6 H)-ones

  • Gómez-SanJuan, Asier
  • Gamo, Ana María
  • Delang, Leen
  • Pérez-Sánchez, Alfonso
  • Amrun, S. N.
  • Abdelnabi, Rana
  • Jacobs, S.
  • Priego, Eva María
  • Camarasa Rius, María José
  • Jochmans, D.
  • Leyssen, Pieter
  • Ng, L. F. P.
  • Querat, Guilles
  • Neyts, Johan
  • Peréz-Pérez, María-Jesús
The re-emergence of chikungunya virus (CHIKV) is a serious global health threat. CHIKV is an alphavirus that is transmitted to humans by Aedes mosquitoes; therefore, their wide distribution significantly contributes to the globalization of the disease. Unfortunately, no effective antiviral drugs are available. We have identified a series of 3-aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones as selective inhibitors of CHIKV replication. New series of compounds have now been synthesized with the aim to improve their physicochemical properties and to potentiate the inhibitory activity against different CHIKV strains. Among these newly synthesized compounds modified at position 3 of the aryl ring, tetrahydropyranyl and N-t-butylpiperidine carboxamide derivatives have shown to elicit potent antiviral activity against different clinically relevant CHIKV isolates with 50% effective concentration (EC) values ranging from 0.30 to 4.5 μM in Vero cells, as well as anti-CHIKV activity in human skin fibroblasts (EC = 0.1 μM), a clinically relevant cell system for CHIKV infection., We thank Caroline Collard and Nick Verstraeten for their excellent technical assistance in the acquisition of the antiviral data. This work has been supported by grants from MINECO/ FEDER SAF2015-64629-C2-1-R and by European Union FP7 Program under SILVER grant agreement no. 260644., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

High-affinity ligands of the colchicine domain in tubulin based on a structure-guided design

  • Bueno, Oskia
  • Estévez-Gallego, Juan
  • Martins, S.
  • Prota, Andrea E.
  • Gago, Federico
  • Gómez-SanJuan, Asier
  • Camarasa Rius, María José
  • Barasoain, Isabel
  • Steinmetz, Michel O.
  • Díaz, José Fernando
  • Peréz-Pérez, María-Jesús
  • Liekens, Sandra
  • Priego, Eva María
Microtubule-targeting agents that bind at the colchicine-site of tubulin are of particular interest in antitumoral therapy due to their dual mechanism of action as antimitotics and vascular disrupting agents. Cyclohexanediones derivatives have been described as a new family of colchicine-domain binders with an association constant to tubulin similar to that of colchicine. Here, the highresolution structures of tubulin in complex with cyclohexanediones TUB015 and TUB075 were solved by X-ray crystallography. A detailed analysis of the tubulin-TUB075 interaction by means of computational affinity maps allowed the identification of two additional regions at the binding site that were addressed with the design and synthesis of a new series of cyclohexanediones with a distal 2-substituted benzofurane. These new compounds showed potent antiproliferative activity with IC50 values in the nM range, arrested cell cycle progression at the G2/M phase and induced apoptosis at sub μM concentrations. Moreover, they caused the destruction of a preformed vascular network in vitro and inhibited the migration of endothelial cells at non-toxic concentrations. Finally, these compounds displayed high affinity for tubulin as substantiated by a Kb value of 2.87 × 108 M−1 which, to the best of our knowledge, represents the highest binding constant measured to date for a colchicine-domain ligand., This project has been supported by the Spanish Ministerio de Economía y Competitividad (SAF2015–64629- C2-1-R to EMP, MJPP. and MJC and SAF2015-64629-C2-2 to F.G.), by the Swiss National Science Foundation (31003A_166608, to MOS) and COST action CM1407 (to MJPP, SL, AP, MS, and JFD). We acknowledge Lizette Van Berckelaer, Eef Meyen and Sam Noppen for excellent technical assistance. We thank V. Olieric and M. Wang for excellent technical assistance with the collection of X-ray data at beamline X06SA of the Swiss Light Source (Paul Scherrer Institut, Villigen PSI, Switzerland). We thank José Fernando Escolar for his help with electron microscopy. We thank ganadería Fernando Díaz for calf brains for tubulin purification. This work was supported in part by grants BFU2016-75319-R (AEI/FEDER, UE) (JFD.) JFD. is a member of the CIB Intramural Program “Molecular Machines for Better Life” (MACBET). We also thank SEQT for the “Ramón Madroñero Award” to O.B., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Novel Class of Cationic and Non-Peptidic Small Molecules as Hits for the Development of Antimicrobial Agents

  • Jiménez, Aranza
  • García, Pablo
  • Puente-Secades, Sofía de la
  • Madrona, Andrés
  • Camarasa Rius, María José
  • Peréz-Pérez, María-Jesús
  • Quintela Fernández, José Carlos
  • García del Portillo, Francisco
  • San-Félix, Ana
Cationic and non-peptide small molecules containing a total of six positive charges arranged on one side and a long aliphatic tail on the other have been synthesized and tested against Gram-positive and Gram-negative bacteria. The positive charges have been contributed by two aminophenol residues. These molecules have showed remarkable antimicrobial activity against Gram-positive bacteria including multidrug-resistant strains. Our structure–activity relationship studies demonstrated the importance of the length and flexibility of the hydrophobic tail for the antimicrobial activity. Importantly, these compounds are non-toxic to eukaryotic cells at the concentration affecting growth in bacteria, reflecting an acceptable margin of safety. The small size and easy synthetic accessibility of our molecules can be of interest for the further development of novel antimicrobials against Gram-positive bacterial pathogens, including multidrug-resistant strains., This research was funded by the Spanish “Plan Nacional de Cooperación Público-Privada, Subprograma INNPACTO” project number IPT-2012-0213 060000, cofinanced by the FEDER program (to J.-C.Q., F.G.-d.P, A.S.-F. and M.-J.P.-P.), “Ministerio de Economia, Industria y Competitividad, Gobierno de España” and “European Regional Development Funds” projects numbers SAF2015-64629-C2-1-R (MINECO/FEDER) (to A.S.-F., M.-J.C. and M.-J.P.-P.) and BIO2016-77639-P (MINECO/FEDER) (to F.G.-d.P.). The Spanish MEC/MINECO is also acknowledged for Garantía Juvenil contracts to A.J. and S.d.l.P., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Conformational mimetics of the α-methyl chalcone TUB091 binding tubulin: Design, synthesis and antiproliferative activity

  • Bueno, Oskia
  • Tobajas, Gloria
  • Quesada, Ernesto
  • Estévez-Gallego, Juan
  • Noppen, Sam
  • Camarasa Rius, María José
  • Díaz, José Fernando
  • Liekens, Sandra
  • Priego, Eva María
  • Peréz-Pérez, María-Jesús
Based on the conformation of the α-methyl chalcone TUB091 in its complex with tubulin, a series of conformational mimetics have been designed and synthesized where the methyl group of the chalcone has been fused to phenyl ring B resulting in 1,2,3,4-tetrahydronaphthalen-2-yl aryl ketones. Among the synthesized compounds, the 5-amino-6-methoxy derivative, with a similar substitution pattern to that of TUB091, showed antiproliferative activity around 20 nM against tumor and endothelial cells. Tubulin binding experiments confirmed its binding to tubulin at the colchicine site with a Kb of 2.4 × 10 M resulting in the inhibition of the in vitro assembly of purified tubulin. Moreover, based on the recently reported complex of combretastatin A4 (CA4) with tubulin, a comparative analysis of the binding mode of CA4 and the α-methyl chalcone to tubulin has been performed., This project has been supported by MINECO (SAF2012-39760- C02-01) and MINECO/FEDER (SAF2015-64629-C2-1-R), and to M.- J.P.-P., E.-M.P. E. Q. and M. J. C. and MINECO/FEDER BFU2016- 75319-R to J.F.D. The authors acknowledge networking contribution by the COST Action CM1407 “Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery” (to M-J. P.-P. S.L. and J.-F.D.) We also would like to acknowledge Eef Meyen and Lizette Van Berckelaer for excellent technical assistance., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prodrugs of Nucleoside Triphosphates as a Sound and Challenging Approach: A Pioneering Work That Opens a New Era in the Direct Intracellular Delivery of Nucleoside Triphosphates

  • Camarasa Rius, María José
Synthetic nucleosides, designed to mimic naturally occurring nucleosides, are important antiviral and anticancer chemotherapeutic agents. However, nucleosides are not active as such and need to be metabolized, step by step, to their corresponding active nucleoside triphosphates (NTPs). This is mediated by phosphorylating enzymes, mainly host cellular kinases with strong specificity for their substrates; in many cases, this specificity prevents efficient conversion into the NTPs. To circumvent this metabolic handicap, successful nucleo(s/t)ide prodrugs have been developed as a valuable concept in the design of effective drugs. The unique concept of the TriPPPro approach, developed by Chris Meier and colleagues, is a powerful tool for the intracellular delivery of active NTPs, bypassing all the phosphorylation steps required by nucleosides to yield the active NTP metabolites. This concept is illustrated herein with general examples., The Spanish MINECO/FEDER (Grant SAF2015-64629-C2-1-R) is acknowledged for financial support. Prof. Federico Gago and Prof. Jan Balzarini are acknowledged for careful reading of this manuscript, Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Approved drugs screening against the nsP1 capping enzyme of Venezuelan equine encephalitis virus using an immuno-based assay

  • Ferreira-Ramos, A. S.
  • Li, C.
  • Eydoux, C.
  • Contreras, J. M.
  • Morice, C.
  • Quérat, G.
  • Gigante, A.
  • Peréz-Pérez, María-Jesús
  • Jung, M. L.
  • Canard, B.
  • Guillemot, J. C.
  • Decroly, E.
  • Coutard, B.
Alphaviruses such as the Venezuelan equine encephalitis virus (VEEV) are important human emerging pathogens transmitted by mosquitoes. They possess a unique viral mRNA capping mechanism catalyzed by the viral non-structural protein nsP1, which is essential for virus replication. The alphaviruses capping starts by the methylation of a GTP molecule by the N7-guanine methyltransferase (MTase) activity; nsP1 then forms a covalent link with mGMP releasing pyrophosphate (GT reaction) and the mGMP is next transferred onto the 5′-diphosphate end of the viral mRNA to form a cap-0 structure. The cap-0 structure decreases the detection of foreign viral RNAs, prevents RNA degradation by cellular exonucleases, and promotes viral RNA translation into proteins. Additionally, reverse-genetic studies have demonstrated that viruses mutated in nsP1 catalytic residues are both impaired towards replication and attenuated. The nsP1 protein is thus considered an attractive antiviral target for drug discovery. We have previously demonstrated that the guanylylation of VEEV nsP1 can be monitored by Western blot analysis using an antibody recognizing the cap structure. In this study, we developed a high throughput ELISA screening assay to monitor the GT reaction through mGMP-nsP1 adduct quantitation. This assay was validated using known nsP1 inhibitors before screening 1220 approved compounds. 18 compounds inhibiting the nsP1 guanylylation were identified, and their IC determined. Compounds from two series were further characterized and shown to inhibit the nsP1 MTase activity. Conversely, these compounds barely inhibited a cellular MTase demonstrating their specificity towards nsP1. Analogues search and SAR were also initiated to identify the active pharmacophore features. Altogether the results show that this HT enzyme-based assay is a convenient way to select potent and specific hit compounds targeting the viral mRNA capping of Alphaviruses., This work was supported by the French research agency ANR “VMTaseIn”, grant ANR-ST14-ASTR-0026, and by the European Union (Seventh Framework Program, Marie Skłodowska-Curie ETN “EUVIRNA”, grant agreement number 264286 and Horizon 2020 Marie Skłodowska-Curie ETN “ANTIVIRALS”, grant agreement number 642434), and by the MINECO/FEDER SAF2015-64629-C2-1-R., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel polyphenols that inhibit colon cancer cell growth affecting cancer cell metabolisms

  • Gómez de Cedrón, Marta
  • Vargas, Teodoro
  • Madrona, Andrés
  • Jiménez, Aranza
  • Peréz-Pérez, María-Jesús
  • Quintela, José Carlos
  • Reglero, Guillermo
  • San-Félix, Ana
  • Ramírez de Molina, Ana
New series of polyphenols with a hydrophilic galloyl-based head and a hydrophobic N-acyl tail, linked through a serinol moiety, have been synthesized and tested against colon cancer cell growth. Our structure activity relationship studies revealed that galloyl moieties are essential for growth inhibition. Moreover, the length of the N-acyl chain is crucial for the activity. Introduction of a (Z) double bond in the acyl chain increased the anticancer properties. Our findings demonstrate that 16, the most potent compound within this series, has inhibitory effects on colon cancer cell growth and metabolism (glycolysis and mitochondrial respiration) at the same time that it activates 59AMP-activated kinase (AMPK) and induces apoptotic cell death. Based on these results, we propose that 16 might reprogram colon cancer cell metabolism through AMPK activation. This might lead to alterations on cancer cell bioenergy compromising cancer cell viability. Importantly, these antiproliferative and proapoptotic effects are selective for cancer cells. Accordingly, these results indicate that 16, with an unsaturated C18 chain, might be a useful prototype for the development of novel colon cancer cell growth inhibitors affecting cell metabolism., This work was supported by the Spanish Plan Nacional de Cooperación Público-Privada, Subprograma INNPACTO (IPT-2012-0213 060000, cofinanced by the FEDER program); the Spanish MINECO [Project SAF2015-64629-C2-1-R (MINECO/FEDER)]; AGL2016-76736-C3-3-R (MINECO/FEDER); and Regional government Comunidad de Madrid (P2013/ABI-2728, ALIBIRD-CM) and European Union Structural Funds. The European Social Fund (Youth Employment Operational Program 2014-2020) supports a contract in practices (to A.J.)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Diphenyl ether derivatives occupy the expanded binding site of cyclohexanedione compounds at the colchicine site in tubulin by movement of the aT5 loop

  • Bueno, Oskia
  • Gargantilla, Marta
  • Estévez-Gallego, Juan
  • Martins, Solange
  • Díaz, José Fernando
  • Camarasa Rius, María José
  • Liekens, Sandra
  • Peréz-Pérez, María-Jesús
  • Priego, Eva María
Microtubule targeting agents represent a very active arena in the development of anticancer agents. In particular, compounds binding at the colchicine site in tubulin are being deeply studied, and the structural information recently available on this binding site allows structure-directed design of new ligands. Structural comparison of our recently reported high resolution X-Ray structure of the cyclohexanedione derivative TUB075 bound to tubulin and the tubulin-DAMA-colchicine complex has revealed a conformational change in the aT5 loop. By a grid-based computational analysis of the tubulinDAMA-colchicine binding site, we have identified a new favourable binding area in the colchicine-site that was unexplored by our lead TUB075. Thus, based on a structure-guided design, new cyclohexanedione derivatives have been synthesized and tested for tubulin binding and in cellular assays. As a result, we have identified diphenyl ether derivatives with IC50 values around 10e40 nM against three different tumor cell lines and affinity constants for tubulin similar to that of colchicine around 107 M 1 . As expected, they halted the cell cycle progression at G2/M phase at concentrations as low as 0.08 mM., This project has been supported by the Spanish Ministerio de Economía y Competitividad SAF2015-64629-C2-1-R (to EMP, MJPP. and MJC) and BFU2016-75319-R (AEI/FEDER, UE) (JFD.) Financial support from CSIC (Proyecto Intramural PIE-201668E079 to MJPP) is also acknowledged. The authors acknowledge networking contribution by COST action CM1407 “Challenging synthesis inspired by nature e from natural products chemistry to drug discovery” (to MJPP, SL, and JFD). JFD. is a member of the CIB Intramural Program ‘‘Molecular Machines for Better Life’’ (MACBET). We acknowledge Lizette Van Berckelaer, Eef Meyen and Sam Noppen for excellent technical assistance. We thank ganadería Fernando Díaz for calf brains for tubulin purification., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Chalcones and Chalcone-mimetic Derivatives as Notch Inhibitors in a Model of T-cell Acute Lymphoblastic Leukemia

  • Quaglio, D.
  • Zhdanovskaya, N.
  • Tobajas, Gloria
  • Cuartas, V.
  • Balducci, S.
  • Christodoulou, M. S.
  • Fabrizi, G.
  • Gargantilla, Marta
  • Priego, Eva María
  • Carmona Pestania, Á.
  • Passarella, D.
  • Screpanti, I.
  • Botta, B.
  • Palermo, R.
  • Mori, M.
  • Ghirga, F.
  • Peréz-Pérez, María-Jesús
Based on hit-likeness and chemical diversity, a number of chalcones and chalcone-mimetic compounds were selected as putative Notch inhibitors. The evaluation of the antiproliferative effect combined with the inhibition of Notch1 expression in KOPTK1 cell line identified compound 18, featuring a tetrahydronaphthalene-based scaffold, as a new promising Notch-blocking agent., The authors acknowledge networking contribution by the COST Action CM1407 “Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery”. V.C. thanks the Universidad del Valle (CIAM- 2017) and the Science, Technology and Innovation Fund- General Royalties System (FCTeI-SGR) under contract BPIN 2013000100007 for a predoctoral fellowship. This work has been supported by Italian Ministry of Education, University and Research - Dipartimenti di Eccellenza - L. 232/2016. This work has been partially supported by a grant from MINECO/ FEDER SAF2015-64629-C2-1-R (to M-J.P.-P and E-M.P), MIUR PNR 2015−2020 (ARS01_00432) (to I.S.), and Sapienza University 2016 Project number RG116154E2- C7A6FB (to I.S.)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Galloyl Carbohydrates with Antiangiogenic Activity Mediated by Capillary Morphogenesis Gene 2 (CMG2) Protein Binding

  • Doyagüez, Elisa G.
  • Carrero, Paula
  • Madrona, Andrés
  • Rodríguez-Salamanca, Patricia
  • Martínez-Gualda, Belén
  • Camarasa Rius, María José
  • Jimeno, M. Luisa
  • Bennallack, P. R.
  • Finnell, J. G
  • Tsang, T. M.
  • Christensen, K. A.
  • San-Félix, Ana
  • Rogers, M. S.
We previously showed that a small molecule of natural origin, 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranose (PGG), binds to capillary morphogenesis gene 2 (CMG2) with a submicromolar IC and also has antiangiogenic activity in vitro and in vivo. In this work, we synthetized derivatives of PGG with different sugar cores and phenolic substituents and tested these as angiogenesis inhibitors. In a high-throughput Förster resonant energy transfer-based binding assay, we found that one of our synthetic analogues (1,2,3,4,6-penta-O-galloyl-β-d-mannopyranose (PGM)), with mannose as central core and galloyl substituents, exhibit higher (up to 10×) affinity for CMG2 than the natural glucose prototype PGG and proved to be a potent angiogenesis inhibitor. These findings demonstrate that biochemical CMG2 binding in vitro predicts inhibition of endothelial cell migration ex vivo and antiangiogenic activity in vivo. The molecules herein described, and in particular PGM, might be useful prototypes for the development of novel agents for angiogenesis-dependent diseases, including blinding eye disease and cancer., This work was supported by the Spanish MINECO [Project SAF2015-64629-C2-1-R (MINECO/FEDER)], the Spanish Agencia Estatal Consejo Superior de Investigaciones Cientif́ - icas (CSIC, Project CSIC201680E079), and NIH R01 EY018829. The Spanish MINECO is also acknowledged for a grant to B.M.-G., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Chikungunya virus drug discovery: still a long way to go?

  • Peréz-Pérez, María-Jesús
  • Delang, Leen
  • Ng, Lisa
  • Priego, Eva María
Introduction: Chikungunya virus (CHIKV) is the etiological agent of a (re)emerging arbovirus infection, chikungunya fever (CHIKF), that represents a serious health problem worldwide for which no antivirals are available. Areas covered: This review covers the efforts performed so far to identify and optimize small molecules that could be useful as antivirals for CHIKV infection, including drug repositioning, phenotypic screening, target-based screening, and structure-based design. This is accompanied by a brief presentation of the replicative cycle of the virus and the role of the viral proteins in CHIKV replication. Expert opinion: In the last decade, and particularly since CHIKV reached the Americas, significant efforts have been made to identify compounds that effectively inhibit CHIKV replication. Unfortunately, these efforts have not led to a clinical candidate. For the years to come, more basic research is required to allow a better understanding of the interplay of the viral proteins among them and with cellular components. Structural information is missing for most of the targets so that structure-based drug design, a strategy that has provided good results in other antiviral fields, has been scarcely applied to this alphavirus., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum

  • Martínez-Gualda, Belén
  • Sun, L.
  • Martí-Marí, Olaia
  • Mirabelli, C.
  • Delang, Leen
  • Neyts, Johan
  • Schols, Dominique
  • Camarasa Rius, María José
  • San-Félix, Ana
We have previously reported a new class of dendrimers with tryptophan (Trp) residues on the surface that show dual antiviral activities against HIV and enterovirus EV71. The prototype compound of this family is a derivative of pentaerythritol with 12 peripheral Trp groups and trivalent spacer arms. Here a novel series of dendrimers with divalent and tetravalent branched arms, instead of the trivalent ones present on the prototype, has been synthesized and its activity against HIV, EV71 and a panel of 16 different viruses and other pathogens has been determined. Convergent or divergent approaches have been used for the synthesis of these compounds. Our findings demonstrate that only compounds with tetravalent branched arms showed the same anti-HIV and anti-EV71 activity of the prototype (low micromolar) and even gain significant antiviral activity against new pathogens such as HSV-2, adenovirus-2, human corona virus and respiratory syncytial virus, being the first members of the Trp dendrimer family that showed activity against those viruses. As the prototype, these compounds also showed low-nanomolar activity against a representative EV71 clinical isolate. Experimental work carried on to determine the mode of action of the most potent IIa, containing tetravalent branched arms, demonstrated that it interacts with the viral envelopes of HIV, EV71 and HSV-2 and thus may prevent virus attachment to the host cell. These results support the interest of this new series of Trp dendrimers and qualify them as useful prototypes for the development of novel inhibitors of viral entry with broad antiviral spectrum., This work has been supported by the Spanish Ministerio de Economía, Industria y Competitividad (MINECO) [project SAF2015- 64629-C2-1-R (MINECO/FEDER)], the Spanish Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC, Project CSIC201680E079), “The Centers of Excellence” of the KU Leuven (EF- 05/15 and PF-10/18), EU FP7 (FP7/2007–2013) Project EUVIRNA (Grant 408 Agreement 264286), EU FP7 SILVER (Contract HEALTH-F3- 2010-260644), a grant from the Belgian Interuniversity Attraction Poles (IAP) Phase VII–P7/45 (BELVIR) and the EU FP7 Industry-Academia Partnerships and Pathways Project AIROPICO. The Spanish MEC/ MINECO is also acknowledged for a grant to B.M.G and the China Scholarship Council (Grant 201403250056) for a grant to L.S. We also thank Charlotte Vanderheydt, Caroline Collard, Kim Donckers, Sandra Claes and Evelyne Van Kerckhove for help with the processing of the antiviral data and Arnaud Boonen and Sam Noppen with the generation of the SPR data., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid

  • Sun, L.
  • Lee, H.
  • Thibaut, H. J.
  • Lanko, K.
  • Rivero-Buceta, E.
  • Bator, C.
  • Martínez-Gualda, Belén
  • Dallmeier, K.
  • Delang, L.
  • Leyssen, P.
  • Gago, Federico
  • San-Félix, Ana
  • Hafenstein, S.
  • Mirabelli, C.
  • Neyts, Johan
Enterovirus A71 (EV-A71) is a non-polio neurotropic enterovirus with pandemic potential. There are no antiviral agents approved to prevent or treat EV-A71 infections. We here report on the molecular mechanism by which a novel class of tryptophan dendrimers inhibits (at low nanomolar to high picomolar concentration) EV-A71 replication in vitro. A lead compound in the series (MADAL385) prevents binding and internalization of the virus but does not, unlike classical capsid binders, stabilize the particle. By means of resistance selection, reverse genetics and cryo-EM, we map the binding region of MADAL385 to the 5-fold vertex of the viral capsid and demonstrate that a single molecule binds to each vertex. By interacting with this region, MADAL385 prevents the interaction of the virus with its cellular receptors PSGL1 and heparan sulfate, thereby blocking the attachment of EV-A71 to the host cells., LS, KL, LD, PL, CM and JN received funding of Belgian Interuniversity Attraction Poles (IAP) Phase VII–P7/45 (BELVIR) and the EU FP7 Industry-Academia Partnerships and Pathways Project AIROPICO. LS received funding of China Scholarship Council (CSC) (Grant 201403250056). HL, CB and SH received a grant with the Pennsylvania Department of Health using Tobacco CURE Funds. ERB, BMG and ASF received the grant “Ministerio de Economia, Industriay Competitividad, Gobierno de España” and “European Regional Development Funds” projects number SAF2015-64629-C2-1-R (MINECO/ FEDER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Design and Synthesis of New 6-Nitro and 6-Amino- 3,3a,4,5-Tetrahydro-2H-Benzo[g]indazole Derivatives: Antiproliferative and Antibacterial Activity

  • Cuartas, Viviana
  • Crespo, María del Pilar
  • Priego, Eva María
  • Persoons, Leentje
  • Daelemans, Dirk
  • Camarasa Rius, María José
  • Insuasty, Braulio
  • Peréz-Pérez, María-Jesús
New substituted benzo[g]indazoles functionalized with a 6-nitro and 6-amino groups have been synthesized by the reaction of benzylidene tetralones with hydrazine in acetic acid. The resulting conformationally-constrained compounds were evaluated for their antiproliferative activity against selected cancer cell lines. The nitro-based indazoles 11a, 11b, 12a and 12b have shown IC50 values between 5–15 μM against the lung carcinoma cell line NCI-H460. Moreover, the nitro compounds were tested for antibacterial activity where compounds 12a and 13b have shown MIC values of 250 and 62.5 μg/mL against N. gonorrhoeae with no hemolytic activity in human red blood cells (RBC)., V.C.: M.P.C. and B.I. thank the Universidad del Valle (CIAM-2017), COLCIENCIAS (110680864255) and the Science, Technology and Innovation Fund-General Royalties System (FCTeI-SGR) under contract BPIN 2013000100007, Colombia. M.-J. P.-P., E.-M. P. and M.-J. C. acknowledge the financial support of SAF2015-64629- C2-1-R and CSIC-PIE-201680E07, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Scaffold Simplification Strategy Leads to a Novel Generation of Dual Human Immunodeficiency Virus and Enterovirus-A71 Entry Inhibitors

  • Martínez-Gualda, Belén
  • Sun, Liang
  • Martí-Marí, Olaia
  • Abdelnabi, Rana
  • Noppen, Sam
  • Bator, Carol M.
  • Quesada, Ernesto
  • Delang, Leen
  • Mirabelli, Carmen
  • Lee, Hyunwook
  • Schols, Dominique
  • Neyts, Johan
  • Hafenstein, Susan
  • Camarasa Rius, María José
  • Gago, Federico
  • San-Félix, Ana
Currently, there are only three FDA-approved drugs that inhibit human immunodeficiency virus (HIV) entry-fusion into host cells. The situation is even worse for enterovirus EV71 infection for which no antiviral therapies are available. We describe here the discovery of potent entry dual inhibitors of HIV and EV71. These compounds contain in their structure three or four tryptophan (Trp) residues linked to a central scaffold. Critical for anti-HIV/EV71 activity is the presence of extra phenyl rings, bearing one or two carboxylates, at the C2 position of the indole ring of each Trp residue. The most potent derivatives, 22 and 30, inhibit early steps of the replicative cycles of HIV-1 and EV-A71 by interacting with their respective viral surfaces (glycoprotein gp120 of HIV and the fivefold axis of the EV-A71 capsid). The high potency, low toxicity, facile chemical synthesis, and great opportunities for chemical optimization make them useful prototypes for future medicinal chemistry studies., This work was supported by the Spanish Plan Nacional (Subprograma Retos) [projects SAF2015-64629-C2-1-R and SAF2015-64629-C2-2-R (MINECO/FEDER)], the Spanish “Ministerio de Ciencia, Innovación y Universidades” (project PID2019-104070RB-C21), and by the Spanish Agencia Estatal Consejo Superior de Investigaciones Cientifí cas (CSIC, Projects CSIC-PIE-201980E100 and CSIC-PIE- 201980E028), “The Centers of Excellence” of the KU Leuven (EF-05/15 and PF-10/18), EU FP7 (FP7/2007−2013) Project EUVIRNA (Grant 408 Agreement 264286), EU FP7 SILVER (Contract HEALTH-F3-2010-260644), a grant from the Belgian Interuniversity Attraction Poles (IAP) Phase VIIP7/ 45 (BELVIR), and the EU FP7 Industry-Academia Partnerships and Pathways Project AIROPICO. The Spanish MEC/MINECO is also acknowledged for grants to B.M.-G. and O.M.-M. and the China Scholarship Council (CSC) (grant 201403250056) for a grant to L.S. S.H. received a grant from the Pennsylvania Department of Health using Tobacco CURE Funds. We also thank Charlotte Vanderheydt, Sandra Claes, and Evelyne Van Kerckhove for helping with the processing of the antiviral data. This work has been awarded with the Janssen (XVIII call) and Esteve (XIX call) prizes within the “Prizes for Young Researchers of the Spanish Society of Medicinal Chemistry (SEQT)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Design and synthesis of new 6-nitro and 6-Amino-3,3a,4,5-Tetrahydro-2H-Benzo[g]indazole derivatives: Antiproliferative and antibacterial activity

  • Cuartas, V.
  • Crespo, M. D. P.
  • Priego, Eva María
  • Persoons, L.
  • Daelemans, D.
  • Camarasa Rius, María José
  • Insuasty, Braulio
  • Peréz-Pérez, María-Jesús
New substituted benzo[g]indazoles functionalized with a 6-nitro and 6-amino groups have been synthesized by the reaction of benzylidene tetralones with hydrazine in acetic acid. The resulting conformationally-constrained compounds were evaluated for their antiproliferative activity against selected cancer cell lines. The nitro-based indazoles 11a, 11b, 12a and 12b have shown IC values between 5-15 μM against the lung carcinoma cell line NCI-H460. Moreover, the nitro compounds were tested for antibacterial activity where compounds 12a and 13b have shown MIC values of 250 and 62.5 μg/mL against N. gonorrhoeae with no hemolytic activity in human red blood cells (RBC)., V.C.: M.P.C. and B.I. thank the Universidad del Valle (CIAM-2017), COLCIENCIAS (110680864255) and the Science, Technology and Innovation Fund-General Royalties System (FCTeI-SGR) under contract BPIN 2013000100007, Colombia. M.-J.P.-P., E.-M.P. and M.-J.C. acknowledge the financial support of SAF2015-64629-C2-1-R and CSIC-PIE-201680E079.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Development of antivirals: medicinal chemistry at the beginning of the process¿and beyond

  • Peréz-Pérez, María-Jesús
The role of medicinal chemistry in drug discovery is crucial but there is significant discussion these days about how far medicinal chemists should be involved in the development process.1 The advances of the different disciplines accompanying drug discovery besides medicinal chemistry itself such as molecular biology, computational chemistry, pharmacokinetics and metabolism studies among others, have increased the challenges to be faced by medicinal chemists. Antiviral drug development has special characteristics when compared to other therapeutic fields in drug discovery. As an example, in a recent review article asking where do recent small molecule clinical development candidates come from,2 it is indicated that phenotypic screening is still one of the main source of antivirals while for other therapeutic areas target-based or fragment-based screening are becoming more relevant. Once a hit with antiviral properties has been identified, its optimization to become a lead is a multiparameter process, that can also be determined by the mechanism of action of the compound. Recent selected examples of the development of antivirals from the literature will be used to highlight this process. In addition, our own experience in triazolopyrimidines as inhibitors of CHIKV replication will be presented to illustrate how proactive and collaborative efforts among academic groups can lead to the identification and optimization of antivirals exploring a new mechanism of action.3-6, Our project in CHIKV inhibitors is financed by a grant from MINECO/FEDER SAF2015-64629-C2-1-R. We also acknowledge the support to REARBOVIR (SAF2016-81856-REDT), a network for antivirals against arboviral diseases
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tryptophan trimers and tetramers inhibit dengue and Zika virus replication by interfering with viral attachment processes

  • Fikatas, A.
  • Vervaeke, P.
  • Martínez-Gualda, Belén
  • Martí-Marí, Olaia
  • Noppen, S.
  • Meyen, E.
  • Camarasa Rius, María José
  • San-Félix, Ana
  • Pannecouque, C.
  • Schols, Dominique
Here, we report a class of tryptophan trimers and tetramers that inhibit (at low micromolar range) dengue and Zika virus infection in vitro. These compounds (AL family) have three or four peripheral tryptophan moieties directly linked to a central scaffold through their amino groups; thus, their carboxylic acid groups are free and exposed to the periphery. Structure-activity relationship (SAR) studies demonstrated that the presence of extra phenyl rings with substituents other than COOH at the N1 or C2 position of the indole side chain is a requisite for the antiviral activity against both viruses. The molecules showed potent antiviral activity, with low cytotoxicity, when evaluated on different cell lines. Moreover, they were active against laboratory and clinical strains of all four serotypes of dengue virus as well as a selected group of Zika virus strains. Additional mechanistic studies performed with the two most potent compounds (AL439 and AL440) demonstrated an interaction with the viral envelope glycoprotein (domain III) of dengue 2 virus, preventing virus attachment to the host cell membrane. Since no antiviral agent is approved at the moment against these two flaviviruses, further pharmacokinetic studies with these molecules are needed for their development as future therapeutic/prophylactic drugs., This work was supported by KU Leuven and the Fonds Wetenschappelijk Onder-zoek (FWO grant PF/10/018), the Spanish MINECO (projects SAF2015-64629-C2-1-Rand SAF2015-64629-C2-2-R [MINECO/FEDER]), and the Spanish Agencia EstatalConsejo Superior de Investigaciones Científicas (CSIC; projects CSIC201680E079 and201980E028). The Spanish MEC/MINECO is also acknowledged for grants to B.M.-G.and O.M.-M, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HIV-1 Envelope Spike MPER: From a Vaccine Target to a New Druggable Pocket for Novel and Effective Fusion Inhibitors

  • Luque, F. Javier
  • Camarasa Rius, María José
Here we highlight a sound and unique work reported by Chen and co-workers entitled “HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes” (Xiao et al., Nat. Chem. Biol. 2020, 16, 529). In this article, the authors identify, by means of a clever antibody-guided strategy, several small molecules as fusion inhibitors of HIV-1 replication acting at the membrane proximal external region (MPER) of the HIV-1 envelope (Env) spike. MPER, which was previously recognized as a vaccine target, emerges as a novel druggable target for the discovery of HIV-1 fusion inhibitors. The compounds (exemplified by dequalinium and dequalinium-inspired analogues) prevent the conformational changes of Env from the prefusion species to the intermediate states required for membrane fusion. This work not only paves the way to novel, specific and useful anti-HIV-1 inhibitors, but also discloses new therapeutic strategies against other infectious diseases., F.J.L. and M.-J.C. thank the Spanish MINECO/FEDER (SAF2015- 64629-C2-1-R, SAF2017-88107, MDM2017-0767, AEI-FEDER UE), MICIU (PID2019-104070RB-C21) and Generalitat de Catalunya (2017SGR1746) for financial support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Protein-ligand complex for structure-based design: impact on the affinity and antitumor activity of new tubulin ligands

  • Bueno, Oskia
  • Estévez-Gallego, Juan
  • Martins, S.
  • Prota, Andrea E.
  • Gago, Federico
  • Gómez-SanJuan, Asier
  • Camarasa Rius, María José
  • Barasoain, Isabel
  • Steinmetz, Michel O.
  • Díaz, José Fernando
  • Liekens, Sandra
  • Peréz-Pérez, María-Jesús
  • Priego, Eva María
Resumen del trabajo presentado en el XVIII Congreso de la Sociedad Española de Química Terapéutica, celebrado en Salamanca (España), del 23 al 26 de enero de 2018, Microtubules, made of ¿ß¿tubulin heterodimers, are the key components of the cytoskeleton and play a crucial role in many cellular processes, such as cell motility, morphogenesis and mitosis.[1] Interference with microtubule dynamics induces cell cycle arrest during mitosis and triggers cell death. Compounds that interact with tubulin, especially those binding at the colchicine domain, have been deeply investigated as anticancer drugs due to their dual mechanism of action as antimitotics and as vascular disrupting agents.[2,3] Our research group has recently described a new family of colchicine¿domain binders, based on a cyclohexanedione skeleton, with potent antiproliferative activity against tumor and endothelial cells.[4] Moreover, to gain insight into the binding mode of these cyclohexanediones, we have determined the crystal structure of ¿ß¿tubulin in complex with our hit compound (TUB075). Based on this detailed information and by applying the affinity maps program cGRILL, a structurebased synthesis of new cyclohexanedione derivatives has been accomplished with the objective of improving their affinity for tubulin and their antitumor activity. Following this approach, we have obtained new compounds with potent antiproliferative activity against tumor and endothelial cells (IC50=8¿31 nM) and with the highest Kb value reported for compounds binding at the colchicine site in tubulin. Additional studies have shown that they arrest cell cycle at G2/M and disrupt a network of endothelial cells. Moreover they keep antiproliferative activity against cell lines overexpressing P¿gp, further supporting the potential of these compounds., The financial support of the Spanish MINECO (SAF2012‐39760‐C02‐01 and SAF 2015‐64629‐C2‐1‐R), Comunidad de Madrid (BIPEDD2; ref P2010/BMD‐2457) and the COST action CM1407 (to M J. P.P., S.L., M.O.S. and J.F.D.) is sincerely acknowledged